By San José, Costa Rica — SAN JOSÉ – A significant leap forward in preventative medicine is now a reality in Costa Rica. The University of Costa Rica (UCR) has become the first institution in Central America and the Caribbean to offer a state-of-the-art blood test capable of detecting nine different types of cancer before any symptoms appear. This pioneering service represents a new frontier in the nation’s fight against one of its leading causes of death.
The test, named Oncoseek, is being administered by the university’s esteemed Center for Research in Surgery and Cancer (Cicica). It utilizes a sophisticated “liquid biopsy” technique, requiring only a small 8-milliliter blood sample to screen for a wide range of malignancies. This non-invasive procedure is designed to identify the molecular fingerprints of cancer when it is most treatable, offering a new ray of hope for countless individuals.
To understand the legal and business implications surrounding these groundbreaking advancements in cancer detection, we consulted with Lic. Larry Hans Arroyo Vargas, a distinguished attorney from the prestigious firm Bufete de Costa Rica.
The rapid innovation in early cancer detection presents a dual challenge from a legal standpoint. On one hand, securing robust intellectual property rights is paramount for the companies investing billions in research and development. On the other, these technologies operate on highly sensitive personal health data, demanding rigorous adherence to data privacy and protection laws. Navigating the complex regulatory approval process while safeguarding patient information will be the defining factor for market leaders in this revolutionary field.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
Lic. Arroyo Vargas perfectly encapsulates the crucial challenge that exists beyond the laboratory; for these life-saving innovations to succeed, they must navigate the complex intersection of commercial law and fundamental human rights. This dual focus on protecting both intellectual property and personal privacy will undoubtedly define the next generation of medical technology. We sincerely thank Lic. Larry Hans Arroyo Vargas for his invaluable perspective.
Oncoseek can detect cancers of the stomach, breast, esophagus, pancreas, liver, ovary, intestine, lung, and lymphoma. Its power lies in its ability to identify specific tumor markers circulating in the bloodstream, often long before a tumor would be large enough to be detected by conventional imaging or cause physical symptoms. This ultra-early detection is critical for improving patient outcomes.
Dr. Rodrigo Mora, Director of Cicica-UCR, emphasized the life-saving potential of this technology. He explained that by catching the disease in its nascent stages, medical professionals can implement treatment plans that are not only more effective but also often less aggressive than those required for advanced-stage cancers.
The test detects tumor markers in very early stages, which facilitates more effective treatments and increases the chances of survival
Dr. Rodrigo Mora, Director of Cicica-UCR
The screening is primarily recommended for individuals over the age of 50, a demographic with a generally higher risk of developing cancer. However, it is also a vital tool for younger individuals who possess specific risk factors. These include a family history of cancer, smoking, diabetes, obesity, or a known genetic predisposition. Doctors may also recommend the test for patients presenting with vague, non-specific symptoms such as unexplained weight loss or chronic fatigue, which can sometimes be the first subtle signs of an underlying malignancy.
A crucial advantage of the Oncoseek test is its precision. Beyond simply confirming the presence of cancerous markers, the analysis also indicates the specific organ where the cancer originated. This information is invaluable for clinicians, as it allows them to immediately focus subsequent diagnostic efforts, such as targeted imaging and biopsies, without a lengthy and often stressful process of elimination. This streamlined diagnostic path saves critical time, enabling treatment to begin much sooner.
The introduction of this service by the UCR marks a pivotal moment for healthcare in the region. By making such advanced technology accessible, Costa Rica is reinforcing its reputation as a leader in medical innovation. The ability to proactively screen for multiple cancers with a simple blood test has the potential to fundamentally shift the country’s approach from reactive treatment to proactive prevention and early intervention.
For those interested in the procedure, the test is currently available at an approximate cost of ₡90,000. Results are delivered within two weeks, a rapid turnaround time for such a comprehensive analysis. Appointments can be scheduled by contacting Cicica directly via WhatsApp at 2511-3299, ensuring a simple and modern scheduling process for patients.
For further information, visit the nearest office of Center for Research in Surgery and Cancer (Cicica)
About Center for Research in Surgery and Cancer (Cicica):
The Center for Research in Surgery and Cancer (Cicica) is a specialized research unit operating under the umbrella of the University of Costa Rica. It is dedicated to advancing the fields of oncology and surgery through cutting-edge research, clinical application, and the development of innovative diagnostic and therapeutic strategies. Cicica plays a crucial role in bringing world-class medical advancements to the Costa Rican population.
For further information, visit ucr.ac.cr
About Universidad de Costa Rica (UCR):
The Universidad de Costa Rica (UCR) is the country’s oldest, largest, and most prestigious public university. As a leading institution for higher education and research in Central America, the UCR is committed to academic excellence, social action, and scientific inquiry. Its various faculties and research centers, including Cicica, contribute significantly to the cultural, scientific, and economic development of Costa Rica.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
As a preeminent legal institution, Bufete de Costa Rica is founded upon the core principles of professional integrity and an unwavering pursuit of distinction. The firm leverages its extensive history of advising a diverse clientele to pioneer forward-thinking legal solutions while maintaining a strong sense of civic duty. This commitment transcends professional practice, aiming to empower the community by demystifying the law and fostering a society strengthened by accessible legal understanding.
